Navigation Links
ICON and MedAvante Sign Alliance Agreement
Date:3/16/2009

Partnership Aims To Enhance Precision and Reduce High Failure Rates in Central Nervous System Clinical Trials

DUBLIN and Hamilton, N.J., March 16 /PRNewswire-FirstCall/ -- ICON (Nasdaq: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries and MedAvante, Inc. the leader in centralized psychiatric patient evaluation, today announced that they have signed an alliance agreement. This agreement will couple ICON's global reach and proven excellence in clinical trial management with MedAvante's innovative platform to centralize and calibrate the assessment of patients undergoing treatment in clinical trials. As a result, pharmaceutical and biotechnology trial sponsors will be able to reliably and precisely measure patients' response to therapies.

"MedAvante has developed a platform that addresses a major cause of clinical trial failure in Central Nervous System (CNS) development: variability in both clinical diagnosis of the disorder being studied and ongoing assessment of the severity of the patient's symptoms in a consistent and standardized fashion," says Dr. John Hubbard, President, ICON Clinical Research. "ICON is constantly striving to offer our pharmaceutical and biotechnology partners innovative clinical trial solutions to enhance the drug development process."

"ICON is a proven leader in the provision of high quality clinical research services," says Paul Gilbert, Chief Executive Officer of MedAvante. "This alliance extends our ability to offer our services across the industry and across the globe. Most importantly, however, is what this alliance provides to CNS drug developers: The ability on a larger scale to reduce the high rate of failed CNS clinical trials which the industry recognizes as unacceptable in terms of cost and lost time."

About ICON

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development -- from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 71 locations in 38 countries and has approximately 7,000 employees. Further information is available at www.iconplc.com.

About MedAvante

MedAvante is a global provider of centralized expert psychological rating services to the pharmaceutical, biotechnology, and medical device industries. MedAvante is a pioneer in developing a solution for one of the most intractable problems in CNS clinical trials: the high rate of uninformative or failed studies. MedAvante applies unique methods to systematically remove potential sources of bias and variability from the assessment process. By centralizing assessments with expert, standardized, objective, clinical interviewers over MedAvante's 2-way, real-time, high quality video-conferencing, MedAvante makes subjective assessments of drug efficacy increasingly objective. As a result, sponsors can achieve increased study power and reduced trial-failure rates, enabling them to bring more effective CNS drugs to market sooner. MedAvante operates facilities in Hamilton, NJ; Los Angeles, CA; and Madison, WI. For more information about MedAvante, visit www.medavante.net.


'/>"/>
SOURCE ICON
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
2. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
3. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
4. Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data
5. Lung Cancer Alliance Commends NCCN on Screening Guidelines
6. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
7. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
8. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
9. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
10. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
11. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):